1. Educational Experience
2012.09–2017.06 PhD in Pharmaceutical Analysis, Key Laboratory of Drug Quality Control and Pharmacovigilance (Ministry of Education), China Pharmaceutical University, Nanjing, China
2007.09–2011.06 BSc in Pharmacy, School of Pharmacy, Soochow University, Suzhou, China
2. Working Experience
2022.07–nowAssociate Professor, School of Pharmacy, China Pharmaceutical University, Nanjing, China
2021.01–2022.06 Lecture, School of Pharmacy, China Pharmaceutical University, Nanjing, China
2019.08–2019.10 Visiting Scholar, Karolinska Institutet, Stockholm, Sweden
2017.11–2020.11 Postdoctoral Researcher, Overseas Laboratory of Karolinska Institutet at Gunma University, Maebashi, Japan
1. Research Projects
(1)National Natural Science Foundation of China, Youth Program, Characterizing the origin and metabolism of 1-methyladenosine in cisplatin resistant non-small cell lung cancer, 2022.01 - 2024.12, No. 82104117, Principal Investigator, In progress.
(2)Jiangsu Natural Science Foundation, Youth Program, Study on the metabolism of 1-methyladenosine and its correlation with cisplatin-induced drug resistance in non-small cell lung cancer, 2021.07 - 2024.06, No. BK20210427, Principal Investigator, In progress.
(3)Japan Society for the Promotion of Science (JSPS), Integrative Metabolomics and Exposomics Study of Severe Asthma in Adults, 2018.4 - 2020.3, No. 18H06121, 19K21239, Principal Investigator, Completed.
2. Representative Research Achievements
(1) Chemical derivatization based-metabolomics method development. A series of novel chemical derivatization reagents were developed and their advantages in improving the chromatographic retention and mass spectrometric response were proved (Anal Chem, 2021; Anal Chem, 2017; Anal Chim Acta, 2019; Anal Chim Acta, 2023). By applying these probes, over 700 metabolites involving >10 metabolic pathways were quantitatively measured with high sensitivity. The developed probes were used to discover novel modified metabolites (e.g., acylation, glycation).
(2) Metabolic regulation study on kidney disease. A quantitative metabolomics strategy was proposed, and the metabolic profile changes of acute kidney injury (AKI) induced by cisplatin were quantitatively evaluated. This strategy is of great benefit for decreasing the false positive rate in biomarker discovery (Chem Res Toxicol, 2016). The metabolic sensitivity differences between renal cortex and medulla in AKI was revealed for the first time, providing important references for further mechanism study (Sci Rep, 2017). In addition, a prediction model of good accuracy (>85%) for predicting the individual difference of cisplatin-induced AKI was constructed (J Proteome Res, 2017). On the basis of above studies, potential targets for AKI intervention were explored by utilizing functional metabolomics, network pharmacology, molecular biology etc. (ZL201811091172.9; Chem Res Toxicol, 2019; Chem Res Toxicol, 2021).
1. Chen, J.;(#) Zhang, P.;(#) Qin, S.; Tan, B.; Li, S.; Tang, S.; Liao, C.; Zhang, Y.; Zhang, Z.; Xu, F., Stepwise solid phase extraction integrated with chemical derivatization for all-in-one injection LC-MS/MS analysis of metabolome and lipidome. Anal Chim Acta 2023, 1241, 340807. (IF: 6.558)
2. Li, W.;(#) Zhang, P.;(#) Hou, X.; Tang, T.; Li, S.; Sun, R.; Zhang, Z.;(*) Xu, F.,(*) Twins labeling derivatization-based LC-MS/MS strategy for absolute quantification of paired prototypes and modified metabolites. Anal Chim Acta 2022, 1193, 339399. (IF: 6.558)
3. Liao, C.; Wang, D.; Qin, S.; Zhang, Y.; Chen, J.; Xu, R.; Xu, F.;(*) Zhang, P.,(*) Inflammatory-Dependent Bidirectional Effect of Bile Acids on NLRP3 Inflammasome and Its Role in Ameliorating CPT-11-Induced Colitis. Front Pharmacol 2022, 13, 677738. (IF: 5.988)
4. Lv, B.; Xu, R.; Xing, X.; Liao, C.; Zhang, Z.; Zhang, P.;(*) Xu, F.,(*) Discovery of Synergistic Drug Combinations for Colorectal Cancer Driven by Tumor Barcode Derived from Metabolomics Big Data. Metabolites 2022, 12 (6). (IF: 5.581)
5. Zhang, Y.; Wang, D.; Lv, B.; Hou, X.; Liu, Q.; Liao, C.; Xu, R.; Zhang, Y.; Xu, F.;(*) Zhang, P.,(*) Oleic Acid and Insulin as Key Characteristics of T2D Promote Colorectal Cancer Deterioration in Xenograft Mice Revealed by Functional Metabolomics. Front Oncol 2021, 11, 685059. (IF: 6.244)
6. Hou, X.;(#) Zhang, P.;(#) Du, H.; Gao, Y.; Sun, R.; Qin, S.; Tian, Y.; Li, J.; Zhang, Y.; Chu, W.; Zhang, Z.;(*) Xu, F.,(*) Prevotella contributes to individual response of FOLFOX in colon cancer. Clin Transl Med 2021, 11 (9), e512. (IF: 11.492)
7. Tang, T.;(#) Zhang, P.;(#) Li, S.; Xu, D.; Li, W.; Tian, Y.; Jiao, Y.; Zhang, Z.;(*) Xu, F.,(*) Absolute Quantification of Acylcarnitines Using Integrated Tmt-PP Derivatization-Based LC-MS/MS and Quantitative Analysis of Multi-Components by a Single Marker Strategy. Anal Chem 2021, 93 (38), 12973-12980. (IF: 6.986)
8. Tan, B.; Chen, J.; Qin, S.; Liao, C.; Zhang, Y.; Wang, D.; Li, S.; Zhang, Z.; Zhang, P.;(*) Xu, F.,(*) Tryptophan Pathway-Targeted Metabolomics Study on the Mechanism and Intervention of Cisplatin-Induced Acute Kidney Injury in Rats. Chem Res Toxicol 2021, 34 (7), 1759-1768. (IF: 3.739)
9. Zhang, P.; Carlsten, C.; Chaleckis, R.; Hanhineva, K.; Huang, M.; Isobe, T.; Koistinen, V. M.; Meister, I.; Papazian, S.; Sdougkou, K.; Xie, H.; Martin, J. W.; Rappaport, S. M.; Tsugawa, H.; Walker, D. I.; Woodruff, T. J.; Wright, R. O.; Wheelock, C. E.,(*) Defining the Scope of Exposome Studies and Research Needs from a Multidisciplinary Perspective. Environ Sci Tech Lett 2021, 8 (10), 839-852. (IF: 7.653)
10. Zhang, P.; Li, W.; Chen, J.; Li, R.; Zhang, Z.; Huang, Y.;(*) Xu, F.,(*) Branched-Chain Amino Acids as Predictors for Individual Differences of Cisplatin Nephrotoxicity in Rats: A Pharmacometabonomics Study. J Proteome Res 2017, 16 (4), 1753-1762. (IF: 3.950)
